M Buechel1, T J Herzog2, S N Westin3, R L Coleman3, B J Monk4, K N Moore5. 1. Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City. Electronic address: Megan-Buechel@ouhsc.edu. 2. Division of Gynecologic Oncology, University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati. 3. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston. 4. Division of Gynecologic Oncology, Arizona Oncology, Phoenix, USA. 5. Section of Gynecologic Oncology, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City.
Abstract
BACKGROUND: Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options. DESIGN: Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed. RESULTS: Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with results from Gynecologic Oncology Group (GOG) 213 and anticipated results from DESKTOP III clinical trials. Chemotherapy backbone has remained relatively unchanged but utilizing non-platinum-based regimens is under investigation. In addition, maintenance therapy with anti-angiogenic therapy and Poly (ADP-ribose) Polymerase (PARP) inhibitors has emerged as the standard of care. Novel combinations, including immunotherapy and anti-angiogenesis agents, may further change the current landscape. CONCLUSIONS: The treatment of recurrent EOC is rapidly changing. Clinical trial design will need to continue to evolve as many novel therapies move to the upfront setting. Ultimately, the treatment of patients with recurrent EOC must incorporate individual patient and tumor factors.
BACKGROUND: Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options. DESIGN: Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed. RESULTS: Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with results from Gynecologic Oncology Group (GOG) 213 and anticipated results from DESKTOP III clinical trials. Chemotherapy backbone has remained relatively unchanged but utilizing non-platinum-based regimens is under investigation. In addition, maintenance therapy with anti-angiogenic therapy and Poly (ADP-ribose) Polymerase (PARP) inhibitors has emerged as the standard of care. Novel combinations, including immunotherapy and anti-angiogenesis agents, may further change the current landscape. CONCLUSIONS: The treatment of recurrent EOC is rapidly changing. Clinical trial design will need to continue to evolve as many novel therapies move to the upfront setting. Ultimately, the treatment of patients with recurrent EOC must incorporate individual patient and tumor factors.
Authors: Philipp Harter; Jalid Sehouli; Alexander Reuss; Annette Hasenburg; Giovanni Scambia; David Cibula; Sven Mahner; Ignace Vergote; Alexander Reinthaller; Alexander Burges; Lars Hanker; Martin Pölcher; Christian Kurzeder; Ulrich Canzler; Karl Ulrich Petry; Andreas Obermair; Edgar Petru; Barbara Schmalfeldt; Domenica Lorusso; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2011-02 Impact factor: 3.437
Authors: Ronald D Alvarez; Ursula A Matulonis; Thomas J Herzog; Robert L Coleman; Bradley J Monk; Maurie Markman Journal: Gynecol Oncol Date: 2016-04-08 Impact factor: 5.482
Authors: Charlotte S Lo; Sanaz Sanii; David R Kroeger; Katy Milne; Aline Talhouk; Derek S Chiu; Kurosh Rahimi; Patricia A Shaw; Blaise A Clarke; Brad H Nelson Journal: Clin Cancer Res Date: 2016-09-06 Impact factor: 12.531
Authors: Amit M Oza; David Cibula; Ana Oaknin Benzaquen; Christopher Poole; Ron H J Mathijssen; Gabe S Sonke; Nicoletta Colombo; Jiří Špaček; Peter Vuylsteke; Holger Hirte; Sven Mahner; Marie Plante; Barbara Schmalfeldt; Helen Mackay; Jacqui Rowbottom; Elizabeth S Lowe; Brian Dougherty; J Carl Barrett; Michael Friedlander Journal: Lancet Oncol Date: 2014-12-04 Impact factor: 41.316
Authors: Shahneen K Sandhu; William R Schelman; George Wilding; Victor Moreno; Richard D Baird; Susana Miranda; Lucy Hylands; Ruth Riisnaes; Martin Forster; Aurelius Omlin; Nathan Kreischer; Khin Thway; Heidrun Gevensleben; Linda Sun; John Loughney; Manash Chatterjee; Carlo Toniatti; Christopher L Carpenter; Robert Iannone; Stan B Kaye; Johann S de Bono; Robert M Wenham Journal: Lancet Oncol Date: 2013-06-28 Impact factor: 41.316
Authors: M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé Journal: Lancet Date: 2003-06-21 Impact factor: 79.321
Authors: Gabriella Macchia; Roberta Lazzari; Nicoletta Colombo; Concetta Laliscia; Giovanni Capelli; Giuseppe Roberto D'Agostino; Francesco Deodato; Ernesto Maranzano; Edy Ippolito; Sara Ronchi; Fabiola Paiar; Marta Scorsetti; Savino Cilla; Rossana Ingargiola; Alessandra Huscher; Anna Maria Cerrotta; Andrei Fodor; Lisa Vicenzi; Donatella Russo; Simona Borghesi; Elisabetta Perrucci; Sandro Pignata; Cynthia Aristei; Alessio Giuseppe Morganti; Giovanni Scambia; Vincenzo Valentini; Barbara Alicja Jereczek-Fossa; Gabriella Ferrandina Journal: Oncologist Date: 2019-10-10
Authors: Anish A Butala; Roshal R Patel; Shwetha Manjunath; Nawar A Latif; Ashley F Haggerty; Joshua A Jones; Neil K Taunk Journal: Adv Radiat Oncol Date: 2020-11-25